Taliglucerase alfa is an intravenous enzyme replacement therapy for Gaucher disease.1 The mechanism of action of taliglucerase alfa is presented in Figure 1. For further information on taliglucerase alfa, please consult your local prescribing information.
Mechanism of action of taliglucerase alfa1,2
C-ANPROM/INT//7568; Date of preparation: September 2020
- Pfizer Canada Inc. ELELYSO® Product Monograph. Last updated August 2017.
- Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441.